SAN DIEGO, CA--(Marketwired - September 13, 2016) - Activate Immunotherapy today announced that the financing agreement with NovaRx has been terminated by mutual agreement.
Activate Immunotherapy will be dissolved and wound up.
CONTACT:
Dr. Stella M. Sung,
Chief Business Officer
Activate Immunotherapy
ssung@activateimmunotherapy.com
